Novo Nordisk reported 118.72B in Debt for its fiscal quarter ending in March of 2025.




Debt Change Date
Bausch Health Companies USD 21.74B 228M Jun/2025
Bristol-Myers Squibb USD 50.93B 1.22B Jun/2025
Eli Lilly USD 39.9B 1.39B Jun/2025
GlaxoSmithKline GBP 17.35B 1.08B Jun/2025
Merck USD 34.84B 2.27B Mar/2025
Novartis USD 31.27B 12M Mar/2025
Novo Nordisk 118.72B 61.75B Mar/2025
Novo Nordisk DKK 118.72B 61.75B Mar/2025
Pacira USD 580.49M 2.88M Jun/2025
Sanofi EUR 22.28B 1.24B Jun/2025
Supernus Pharmaceuticals USD 31.77M 531K Jun/2025